SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

Key Takeaways The EU approved Dupixent for moderate-to-severe chronic spontaneous urticaria in patients 12 and older.Study A and C showed Dupixent reduced itch and hives and improved disease control versus placebo at 24 weeks.Safety findings from all LIBERTY-CUPID studies aligned with the known safety profile of Dupixent.Sanofi (SNY) and partner Regeneron (REGN) announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (“CS ...